plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients
NCT ID: NCT04622826
Last Updated: 2020-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
50 participants
INTERVENTIONAL
2020-05-15
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Efficacy is evaluated by the number of patients who will improve their clinical condition and will not be admitted to ITU. .Safety is considered in relation to adverse reactions to plasma infusion.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
sequential immune plasma infused patients
immune covid 19 plasma infusion
immune plasma
immune covid 19 plasma infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
immune plasma
immune covid 19 plasma infusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* hospitalized patients with positive covid-19 swab with respiratory symptoms and CT confirmation of covid-19 chest disease admitted to non ITU recovery area.
* informed consent for plasma infusion
* informed consent to blood samples storing for future studies.
Exclusion Criteria
* immunoglobulin infusion in the last month
contraindication to transfusion or previous adverse reaction
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Azienda USL Toscana Nord Ovest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
mirko lombardi
consultant
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
antonella vincenti
Role: PRINCIPAL_INVESTIGATOR
ospedale delle Apuane
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ospedale delle Apuane
Massa, Tuscany, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
mirko lombardi
Role: primary
antonella vincenti
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ATNONordOvest
Identifier Type: -
Identifier Source: org_study_id